23andMe Bankruptcy Sparks Fears Over Fate of Customers’ DNA Data

Genetic testing giant 23andMe has filed for bankruptcy triggering urgent questions about the security of millions of customers’ DNA profiles. The California-based firm once worth billions now seeks a buyer amid financial collapse. Privacy advocates warn a sale could put sensitive personal data at risk in uncharted legal waters.

The company boasts over 15 million users who’ve shared saliva samples for ancestry and health insights. A 2023 data breach already exposed nearly 7 million profiles denting trust. Now bankruptcy raises the stakes as experts fear a new owner might exploit this genetic trove for profit or worse.

23andMe insists any buyer must follow strict privacy laws to protect customer information. Yet critics note those rules offer little shield if policies shift post-sale. California’s Attorney General has urged users to delete their data preemptively citing the firm’s shaky finances and past lapses.

The firm’s downfall stems from fading demand for one-off DNA kits and failed drug research ventures. Once a darling of Silicon Valley its stock has crashed over 99 percent since 2021. Bankruptcy filings this week aim to offload assets including the DNA database that fueled its early hype.

Privacy risks extend beyond users to their relatives whose genes are indirectly mapped. A buyer could sell this data to insurers or employers raising ethical red flags. Advocates for stronger regulations say the case exposes gaps in how the U.S. safeguards biometric information.

Customers are scrambling to erase their profiles though deletion may not erase all traces. 23andMe’s past partnerships with pharma giants like GSK hint at how coveted its data remains. Legal experts warn that bankruptcy courts prioritize creditors over consumer protections leaving users vulnerable.

Lawmakers are eyeing the fiasco as a wake-up call for genetic privacy reforms. Progressive voices demand bans on data sales to curb exploitation by corporations or governments. For now users face a stark choice between trusting a sale process or racing to opt out before it’s too late.

The 23andMe saga underscores the fragile line between innovation and accountability. As the firm seeks a lifeline through bankruptcy its customers grapple with the fallout of a broken promise. Whether their DNA stays safe may hinge on who claims this biotech wreck and what they do with its most prized asset.